The relationship between the high-density lipoprotein (HDL)-associated sphingosine-1-phosphate (S1P) and coronary in-stent restenosis

Jing, Xiaodong; Wei, Xiaoming; Deng, Songbai; Du, Jianlin; Liu, Yajie; Qiang, Sheng

doi:10.1016/j.cca.2015.04.038

Cited by 27 publications

(18 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is worth noting that in one of these studies the content of S1P in HDL was inversely related to the incidence of coronary artery disease independent of the plasma concentration of HDL cholesterol [192]. Likewise, decreased concentrations of both S1P and HDL-bound S1P have been reported in patients with coronary in-stent restenosis compared with healthy subjects [209]. Accordingly, HDL-bound S1P has been further revealed as an independent predictor of this coronary event in affected patients [209], but it fails to predict the severity of coronary heart disease burden [208].…”

Section: Circulating S1p/apom In Cardiac Diseasesmentioning

confidence: 91%

“…Likewise, decreased concentrations of both S1P and HDL-bound S1P have been reported in patients with coronary in-stent restenosis compared with healthy subjects [209]. Accordingly, HDL-bound S1P has been further revealed as an independent predictor of this coronary event in affected patients [209], but it fails to predict the severity of coronary heart disease burden [208].…”

Section: Circulating S1p/apom In Cardiac Diseasesmentioning

confidence: 99%

See 1 more Smart Citation

Novel Insights into the Role of HDL-Associated Sphingosine-1-Phosphate in Cardiometabolic Diseases

Diarte-Añazco

Méndez-Lara

Pérez

et al. 2019

IJMS

View full text Add to dashboard Cite

Sphingolipids are key signaling molecules involved in the regulation of cell physiology. These species are found in tissues and in circulation. Although they only constitute a small fraction in lipid composition of circulating lipoproteins, their concentration in plasma and distribution among plasma lipoproteins appears distorted under adverse cardiometabolic conditions such as diabetes mellitus. Sphingosine-1-phosphate (S1P), one of their main representatives, is involved in regulating cardiomyocyte homeostasis in different models of experimental cardiomyopathy. Cardiomyopathy is a common complication of diabetes mellitus and represents a main risk factor for heart failure. Notably, plasma concentration of S1P, particularly high-density lipoprotein (HDL)-bound S1P, may be decreased in patients with diabetes mellitus, and hence, inversely related to cardiac alterations. Despite this, little attention has been given to the circulating levels of either total S1P or HDL-bound S1P as potential biomarkers of diabetic cardiomyopathy. Thus, this review will focus on the potential role of HDL-bound S1P as a circulating biomarker in the diagnosis of main cardiometabolic complications frequently associated with systemic metabolic syndromes with impaired insulin signaling. Given the bioactive nature of these molecules, we also evaluated its potential of HDL-bound S1P-raising strategies for the treatment of cardiometabolic disease.

show abstract

Section: Circulating S1p/apom In Cardiac Diseasesmentioning

confidence: 91%

Section: Circulating S1p/apom In Cardiac Diseasesmentioning

confidence: 99%

Novel Insights into the Role of HDL-Associated Sphingosine-1-Phosphate in Cardiometabolic Diseases

Diarte-Añazco

Méndez-Lara

Pérez

et al. 2019

IJMS

View full text Add to dashboard Cite

show abstract

“…117 In a nested case control study involving 204 subjects stratified by HDL-cholesterol from the Copenhagen City Heart Study, S1P levels in the HDL-containing fraction of serum (depleted of apoB-containing lipoproteins) were inversely associated with the occurrence of ischemic heart disease. 108 Although a crosssectional analysis in patients with CAD showed that patients who possessed HDL-S1P levels in the lowest quartile were more likely to demonstrate in-stent restenosis than patients in the higher quartiles, 118 the amount of HDL-associated S1P was not predictive for the development of restenosis during follow-up in CAD patients after percutaneous coronary intervention. 117 Additional findings of studies on HDL isolated from acute myocardial infarction patients suggest that a reduced S1P content of HDL impairs the capacities to stimulate endothelial nitric oxide production 119 and to inhibit endothelial apoptosis.…”

Section: Sphingolipidsmentioning

confidence: 99%

Dysfunctional high-density lipoproteins in coronary heart disease: implications for diagnostics and therapy

Annema

Eckardstein

2016

Translational Research

View full text Add to dashboard Cite

Low plasma levels of high-density lipoprotein (HDL) cholesterol are associated with increased risks of coronary heart disease. HDL mediates cholesterol efflux from macrophages for reverse transport to the liver and elicits many anti-inflammatory and anti-oxidative activities which are potentially antiatherogenic. Nevertheless, HDL has not been successfully targeted by drugs for prevention or treatment of cardiovascular diseases. One potential reason is the targeting of HDL cholesterol which does not capture the structural and functional complexity of HDL particles. Hundreds of lipid species and dozens of proteins as well as several microRNAs have been identified in HDL. This physiological heterogeneity is further increased in pathologic conditions due to additional quantitative and qualitative molecular changes of HDL components which have been associated with both loss of physiological function and gain of pathologic dysfunction. This structural and functional complexity of HDL has prevented clear assignments of molecules to the functions of normal HDL and dysfunctions of pathologic HDL. Systematic analyses of structure-function relationships of HDL-associated molecules and their modifications are needed to test the different components and functions of HDL for their relative contribution in the pathogenesis of atherosclerosis. The derived biomarkers and targets may eventually help to exploit HDL for treatment and diagnostics of cardiovascular diseases.

show abstract

“…The potential clinical consequences are illustrated by recent studies demonstrating increased risk of restenosis in patients with reduced HDL-S1P. 35 The question arises as to how glycation may provoke loss of S1P from HDL. The major determinant of S1P binding to HDL is apoM.…”

Section: D F Ementioning

confidence: 99%

Diabetes Mellitus Is Associated With Reduced High-Density Lipoprotein Sphingosine-1-Phosphate Content and Impaired High-Density Lipoprotein Cardiac Cell Protection

Brinck

Thomas

Lauer

et al. 2016

ATVB

View full text Add to dashboard Cite

Objective— The dyslipidemia of type 2 diabetes mellitus has multiple etiologies and impairs lipoprotein functionality, thereby increasing risk for cardiovascular disease. High-density lipoproteins (HDLs) have several beneficial effects, notably protecting the heart from myocardial ischemia. We hypothesized that glycation of HDL could compromise this cardioprotective effect. Approach and Results— We used in vitro (cardiomyocytes) and ex vivo (whole heart) models subjected to oxidative stress together with HDL isolated from diabetic patients and nondiabetic HDL glycated in vitro (methylglyoxal). Diabetic and in vitro glycated HDL were less effective ( P <0.05) than control HDL in protecting from oxidative stress. Protection was significantly, inversely correlated with the degree of in vitro glycation ( P <0.001) and the levels of hemoglobin A1c in diabetic patients ( P <0.007). The ability to activate protective, intracellular survival pathways involving Akt, Stat3, and Erk1/2 was significantly reduced ( P <0.05) using glycated HDL. Glycation reduced the sphingosine-1-phosphate (S1P) content of HDL, whereas the S1P concentrations of diabetic HDL were inversely correlated with hemoglobin A1c ( P <0.005). The S1P contents of in vitro glycated and diabetic HDL were significantly, positively correlated (both <0.01) with cardiomyocyte survival during oxidative stress. Adding S1P to diabetic HDL increased its S1P content and restored its cardioprotective function. Conclusions— Our data demonstrate that glycation can reduce the S1P content of HDL, leading to increased cardiomyocyte cell death because of less effective activation of intracellular survival pathways. It has important implications for the functionality of HDL in diabetes mellitus because HDL-S1P has several beneficial effects on the vasculature.

show abstract

The relationship between the high-density lipoprotein (HDL)-associated sphingosine-1-phosphate (S1P) and coronary in-stent restenosis

Cited by 27 publications

References 16 publications

Novel Insights into the Role of HDL-Associated Sphingosine-1-Phosphate in Cardiometabolic Diseases

Novel Insights into the Role of HDL-Associated Sphingosine-1-Phosphate in Cardiometabolic Diseases

Dysfunctional high-density lipoproteins in coronary heart disease: implications for diagnostics and therapy

Diabetes Mellitus Is Associated With Reduced High-Density Lipoprotein Sphingosine-1-Phosphate Content and Impaired High-Density Lipoprotein Cardiac Cell Protection

Contact Info

Product

Resources

About